Clearside Biomedical, Inc. (CLSDQ)
OTC PINK OTC PINK Primary Summary
Clearside Biomedical, Inc. (CLSDQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clearside Biomedical, Inc. ever had a stock split?
Clearside Biomedical, Inc. Profile
| Biotechnology Industry | Healthcare Sector | George Lasezkay CEO | OTC PINK Exchange | 185063203 CUSIP |
| US Country | 32 Employees | - Last Dividend | - Last Split | 2 Jun 2016 IPO Date |
Overview
Clearside Biomedical, Inc. is a pioneering biopharmaceutical company founded in 2011, with its headquarters situated in Alpharetta, Georgia. The company is at the forefront of innovating therapeutic delivery specifically to the posterior segment of the eye via the suprachoroidal space. This novel approach is intended to improve the treatment of various eye diseases by targeting the delivery of drugs directly to the affected areas. Clearside Biomedical's commitment to eye health is further evidenced through its collaborative efforts with notable entities such as Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. These collaborations aim to enhance and extend the capabilities and reach of its technologies and offerings in the ophthalmic market.
Products and Services
- XIPERE
- CLS-AX (Axitinib Injectable Suspension)
XIPERE is a cutting-edge therapeutic offering from Clearside Biomedical, comprising a triamcinolone acetonide suprachoroidal injectable suspension. This product is specifically designed for the treatment of uveitis macular edema, a condition characterized by inflammation and swelling in the eye that can lead to severe vision impairment. By delivering the medication via the suprachoroidal space, XIPERE aims to provide targeted relief and treatment outcomes that could potentially surpass those of conventional methods.
CLS-AX represents another frontier in Clearside Biomedical's innovative product lineup, being an axitinib injectable suspension for suprachoroidal injection. Currently in Phase IIb clinical trials, CLS-AX is being developed to treat wet age-related macular degeneration (wet AMD), a leading cause of blindness in older adults. Through its unique delivery system and mechanism of action, CLS-AX holds the promise of significantly improving treatment efficacy and patient outcomes in managing this chronic eye condition.
